Targeting Cancer at the Nuclear Pore

J Clin Oncol. 2016 Dec;34(34):4180-4182. doi: 10.1200/JCO.2016.67.5637. Epub 2016 Oct 23.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Exportin 1 Protein
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Hydrazines / adverse effects
  • Hydrazines / therapeutic use*
  • Karyopherins / antagonists & inhibitors
  • Karyopherins / genetics
  • Karyopherins / metabolism
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Nuclear Pore / drug effects*
  • Nuclear Pore / metabolism
  • Nuclear Pore / pathology
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Signal Transduction / drug effects*
  • Treatment Outcome
  • Triazoles / adverse effects
  • Triazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Hydrazines
  • Karyopherins
  • Receptors, Cytoplasmic and Nuclear
  • Triazoles
  • selinexor